Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139013

Published: 2020

Journal Articles

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Xiaorong Gu, PhD, Rita Tohme, PhD, Benjamin K. Tomlinson, MD, Lisa Durkin, Caroline Schuerger, Asmaa M Zidan, MB, BCh, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Ronald Sobecks, MD, Betty K. Hamilton, MD, Alan Lichtin, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 537.

https://doi.org/10.1182/blood-2019-125823

Published: 2019

Journal Articles

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Yasunobu Nagata, MD PhD, Ran Zhao, Hassan Awada, Cassandra M Kerr, MS, Abhinav Goyal, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Jacob Scott, MD, Mikkael A. Sekeres, MD MS, Brian P. Hobbs, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1716.

https://doi.org/10.1182/blood-2019-127285

Published: 2019

Journal Articles

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 16.

https://doi.org/10.1182/blood-2019-130319

Published: 2019

Journal Articles

Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis

Hassan Awada, Arda Durmaz, Yasunobu Nagata, MD PhD, Teodora Kuzmanovic, Ashwin Kishtagari, MBBS, Jibran Durrani, Cassandra M Kerr, MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Manja Meggendorfer, PhD, Aziz Nazha, MD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1406.

https://doi.org/10.1182/blood-2019-132031

Published: 2019

Journal Articles

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Yasunobu Nagata, MD PhD, Hideki Makishima, MD PhD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Hassan Awada, Vera Adema, PhD, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2992.

https://doi.org/10.1182/blood-2019-128893

Published: 2019

Journal Articles

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Christina A. Snider, BA, Kevin Fung, Francesca Gould, Vera Adema, PhD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, Hassan Awada, MD, Milo Co, Teodora Kuzmanovic, BA, Bhumika J. Patel, MD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 2696.

https://doi.org/10.1182/blood-2019-126311

Published: 2019

Journal Articles

Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?

Abby Statler, PhD MPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Sudipto Mukherjee, MD PhD MPH, Kimberly Bell, MBA, RN, BSN, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 381.

https://doi.org/10.1182/blood-2019-129096

Published: 2019

Journal Articles

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Blood (2019) 134 (Supplement_1): 3836.

https://doi.org/10.1182/blood-2019-128853

Published: 2019

Journal Articles

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Ashwin Kishtagari, MBBS, Hassan Awada, Reda Z. Mahfouz, MD PhD, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Alan Lichtin, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 1279.

https://doi.org/10.1182/blood-2019-130579

Published: 2019

Journal Articles

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Yihong Guan, PhD, Anand D. Tiwari, PhD, James G Phillips, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Daniel Lindner, MD PhD, Manja Meggendorfer, PhD, Mohamed Abazeed, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 880.

https://doi.org/10.1182/blood-2019-131920

Published: 2019

Journal Articles

Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States

Raffi Tchekmedyian, BS, Tomas Radivoyevitch, PhD, Aaron T. Gerds, MDMS, Aziz Nazha, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Jaroslaw P. Maciejewski, Matt Kalaycio, MD, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MDPhDMPH

Blood (2018) 132 (Supplement 1): 371.

https://doi.org/10.1182/blood-2018-99-119661

Published: 2018

Journal Articles

Distinct Features of Chip-Derived and De Novo MDS

Blood (2018) 132 (Supplement 1): 2572.

https://doi.org/10.1182/blood-2018-99-117763

Published: 2018

Journal Articles

Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Bhumika J. Patel, MD, Shimoli Vipul Barot, MD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Hassan Awada, MD, Metis Hasipek, PhD, Swapna Thota, MD, Tomas Radivoyevitch, PhD, Anjali S. Advani, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 2590.

https://doi.org/10.1182/blood-2018-99-119852

Published: 2018

Journal Articles

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Yihong Guan, Anand D. Tiwari, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Yvonne Parker, Cassandra M. Hirsch, Amy C Graham, BS, MS, Yasunobu Nagata, Bartlomiej P. Przychodzen, Aziz Nazha, Daniel Lindner, MD PhD, Tomas Radivoyevitch, PhD, James G Phillips, PhD, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4345.

https://doi.org/10.1182/blood-2018-99-117186

Published: 2018

Journal Articles

Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation

Blood (2018) 132 (Supplement 1): 4346.

https://doi.org/10.1182/blood-2018-99-119712

Published: 2018

Journal Articles

Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)

Blood (2018) 132 (Supplement 1): 4351.

https://doi.org/10.1182/blood-2018-99-119896

Published: 2018

Journal Articles

BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden

Louis Williams, MD MBA, Teodora Kuzmanovic, BA, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Yogenthiran Saunthararajah, MD, Hassan Awada, MD, Vera Adema, PhD, Amy C Graham, BS, MS, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Aziz Nazha, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 4352.

https://doi.org/10.1182/blood-2018-99-116802

Published: 2018

Journal Articles

Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML

Teodora Kuzmanovic, Bhumika J. Patel, MD, Yasunobu Nagata, Hassan Awada, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Srinivasa Reddy Sanikommu, MD, Louis Williams, MD MBA, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MD MS, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 4353.

https://doi.org/10.1182/blood-2018-99-120059

Published: 2018

Journal Articles

Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS)

Blood (2018) 132 (Supplement 1): 104.

https://doi.org/10.1182/blood-2018-99-118861

Published: 2018

NARROW

The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States

Distinct Features of Chip-Derived and De Novo MDS

Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation

Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)

BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden

Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML

Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only